View in Other Languages

Universal Biosensors, Inc. (ASX:UBI) today announced that LifeScan's new product, OneTouch Verio (R) has been made available for sale in France. The OneTouch Verio (R) incorporates technology developed by Universal Biosensors and addresses the rapidly growing Self Monitoring Blood Glucose (SMBG) market.

Speaking about the launch, UBI Executive Chairman, Andy Denver said, "LifeScan's launch of the OneTouch Verio (R) into the French market represents another significant milestone for UBI. France is a major SMBG market with one of the highest growth rates in Europe. LifeScan's continued roll out of OneTouch Verio (R) across Europe has been widely anticipated and follows the successful launch of the device in the Netherlands in January 2010 and in Australia in September 2010."

GlobalData reports that the SMBG market in France is estimated to reach $800 million in 2015 with a compound annual growth rate over the next five years of 11%. Systematic diabetes screening programs in European countries like France are reducing the incidence of undiagnosed diabetes cases and increasing the uptake of SMBG devices in those markets. GlobalData reports that LifeScan is one of four leaders in the European SMBG market with an estimated market share of 19% (2008). The OneTouch Verio (R) has significant advantages in the highly competitive SMBG industry including reliable accuracy and no requirement for calibration code entry.

About Universal Biosensors Inc.

Universal Biosensors (ASX:UBI) is a medical diagnostics company focused on the research, development and manufacture of diagnostic test systems for point-of-care professional and home use.



Mr Andrew Denver
Tel: +61-3-9213-9000
Universal Biosensors Inc.

Link: Universal Biosensors (ASX:UBI) Announces Launch Of OneTouch Verio (R) In France by LifeScan

Related Companies

Universal Biosensors Inc.

Related Industry Topics:
Biotech Financial General Health & Pharm General